Newsroom of

Phoenix Nest Biotech

Follow on Social Network

Phoenix Nest Inc. Licenses a Sanfilippo Syndrome Gene Therapy From the University of Manchester and is Preparing for a Clinical Trial

Phoenix Nest Inc. exclusively licensed a gene therapy for Sanfilippo syndrome (also known as Mucopolysaccharidosis IIIC, (MPSIIIC)) from The University of Manchester through its IP commercialization arm UMI3 Ltd. MPS IIIC is a devastating neurodegenerative lysosomal storage disorder of childhood…

Phoenix Nest Inc., Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and Washington University in St. Louis Announce a New NIH Grant for Sanfilippo Syndrome (MPSIIID)

The National Institute of Neurological Disorders and Stroke at the National Institutes of Health (NIH) recently awarded $5,612,276 in SBIR Phase IIB grant funding to Phoenix Nest, Inc., The Division of Medical Genetics at the Los Angeles Biomedical Research Institute…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login